供者与受者糖尿病对肾移植患者及移植物生存的影响
本研究基于澳大利亚和新西兰透析与移植登记处2003至2022年数据,分析11343例首次接受 deceased-donor 肾移植的成人受者。Cox模型显示,仅当供者与受者均患糖尿病时,移植物生存(aHR 1.70)和患者生存(aHR 1.77)显著变差;非糖尿病受者接受糖尿病供肾未见生存影响。
要点
- 供受者均糖尿病时移植物和患者生存显著变差,应谨慎考虑。
- 非糖尿病受者接受糖尿病供肾未影响移植物或患者生存。
- 仅受者糖尿病时移植物生存未显著降低,但患者生存最差。
核心结论
- 供受者均糖尿病组合与更差的移植物和患者生存相关,应谨慎考虑。
- 非糖尿病受者使用糖尿病供肾未影响移植物或患者生存,支持继续使用。
研究设计与样本
- 基于ANZDATA登记处的回顾性队列研究,纳入2003至2022年首次接受 deceased-donor 肾移植的成人受者11343例。
- 使用Cox比例风险模型比较死亡删失移植物生存和患者生存,逻辑回归分析排斥,线性混合模型分析eGFR随时间变化。
主要发现
- 死亡删失移植物生存仅在供受者均糖尿病组降低(aHR 1.70,95%CI 1.15-2.51,P=0.008)。
- 糖尿病患者生存最差,尤其供受者均糖尿病组(aHR 1.77,95%CI 1.33-2.37,P<0.001)。
- 接受糖尿病供肾的受者排斥无差异,eGFR仅轻微降低。
关键数值与推荐
- 供受者均糖尿病组移植物生存aHR 1.70(95%CI 1.15-2.51,P=0.008)。
- 供受者均糖尿病组患者生存aHR 1.77(95%CI 1.33-2.37,P<0.001)。
临床怎么用
- 非糖尿病受者可使用糖尿病供肾,未见移植物或患者生存受损。
- 供受者均糖尿病时需谨慎评估移植风险与获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: With the growing demand for kidney transplants, kidneys from donors with diabetes mellitus are used more frequently. This raises the concerning possibility that a kidney with early-stage diabetic nephropathy may be transplanted into a recipient who subsequently develops posttransplant dysglycemia; however, it is unclear what impact this will have on graft function and survival. This study investigated graft and patient survival when the donor, recipient, or both have diabetes. METHODS: Data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry were used to analyze first-time adult recipients of deceased-donor kidneys between 2003 and 2022. Cox proportional hazards models were used to compare primary outcomes of death-censored graft survival and patient survival across combinations of donor and recipient diabetic status. Secondary outcomes of rejection and estimated glomerular filtration rate (eGFR) over time were analyzed with logistic regression and linear mixed models, respectively. RESULTS: The 11,343 recipients included 7377 donor-recipient nondiabetic pairs (D-/R-), 3253 diabetic recipients-nondiabetic donors (D-/R+), 524 nondiabetic recipients-diabetic donors (D+/R-), and 189 both donor and recipient diabetic (D+/R+). Death-censored graft survival was reduced only in the D+/R+ group (adjusted hazard ratio [aHR]: 1.70, 95% confidence interval [CI]: 1.15-2.51, P = 0.008). Diabetic recipients had the poorest survival, particularly in the D+/R+ group (aHR: 1.77, 95% CI: 1.33-2.37, P < 0.001). There was no difference in rejection and only a minor reduction in eGFR for recipients of diabetic donor kidneys. CONCLUSION: The D+/R+ combination is associated with inferior graft and patient survival and should be considered cautiously. This study supports continued use of diabetic donors with no impact on graft or patient survival in nondiabetic recipients.
引用
- Orsillo A, Kholmurodova F, Clayton PA, et al. The Impact of Donor and Recipient Diabetes on Patient and Graft Survival in Kidney Transplant Recipients. Kidney Int Rep. 2025. PMID: 41278352. doi:10.1016/j.ekir.2025.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。